上海，2026年1月12日，藥明康德（股票代碼：603259.SH/2359.HK）發(fā)布2025年度業(yè)績預(yù)增公告，披露主要經(jīng)營數(shù)據(jù)預(yù)測，其中持續(xù)經(jīng)營業(yè)務(wù)收入同比增長約21.4%。

公告重要提示如下：

藥明康德持續(xù)聚焦獨(dú)特的“一體化、端到端”CRDMO業(yè)務(wù)模式，緊抓客戶對賦能需求的確定性，不斷拓展新能力、建設(shè)新產(chǎn)能，持續(xù)優(yōu)化生產(chǎn)工藝和提高經(jīng)營效率，推動業(yè)務(wù)持續(xù)穩(wěn)健增長，高效極致賦能客戶并致力于將更多新藥、好藥帶給全球病患。

• 營業(yè)收入：預(yù)計(jì)2025年全年實(shí)現(xiàn)約人民幣454.6億元，同比增長約15.8%，其中持續(xù)經(jīng)營業(yè)務(wù)收入同比增長約21.4%。

• 經(jīng)調(diào)整Non-IFRS歸母凈利潤：預(yù)計(jì)2025年全年實(shí)現(xiàn)約人民幣149.6億元，同比增長約41.3%。

• 扣非歸母凈利潤：預(yù)計(jì)2025年全年實(shí)現(xiàn)約人民幣132.4億元，同比增長約32.6%，與經(jīng)調(diào)整Non-IFRS歸母凈利潤增速相比主要受到匯率波動的影響。

• 歸母凈利潤：預(yù)計(jì)2025年全年實(shí)現(xiàn)約人民幣191.5億元，同比增長約102.6%，其中包含了出售聯(lián)營公司部分股權(quán)以及剝離部分業(yè)務(wù)所獲得的投資收益；預(yù)計(jì)2025年全年基本每股收益約人民幣6.70元/股，同比增長約104.3%。

數(shù)據(jù)說明：

以上預(yù)告數(shù)據(jù)僅為公司初步核算數(shù)據(jù)。藥明康德將在2026年3月24日正式發(fā)布經(jīng)審計(jì)的2025年年度報(bào)告時提供更多詳細(xì)信息。

更多信息，請見公司相關(guān)公告：

掃碼查看公告

關(guān)于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫(yī)藥及生命科學(xué)行業(yè)值得信賴的合作伙伴和重要貢獻(xiàn)者，致力于通過提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，推動全球醫(yī)藥健康創(chuàng)新。公司在亞洲、歐洲、北美等地均設(shè)有運(yùn)營基地，依托獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的約6,000家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請?jiān)L問公司網(wǎng)站：www.wuxiapptec.com

WuXi AppTec Issues Positive Profit Alert for the Full Year of 2025

Shanghai, Jan 12, 2026 – WuXi AppTec (stock code: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today issued a Positive Profit Alert for the full year of 2025, disclosing forecasts of key operational data, with revenue from Continuing Operations growing by approximately 21.4% year-over-year.

Important notices of the announcement are as follows:

WuXi AppTec maintains a laser focus on its unique, integrated and end-to-end CRDMO business model. In response to ongoing customer demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. This strategy is driving sustained long-term business growth, delivering highly efficient and exceptional services to customers, and helping to bring groundbreaking therapies to patients worldwide.

• Total revenuefor the full year of 2025 is expected to be approximately RMB45.46 billion, representing a year-over-year increase of approximately 15.8%, with revenue from Continuing Operations growing by approximately 21.4% year-over-year.

• Adjusted non-IFRS net profitfor the full year of 2025 is expected to be approximately RMB14.96 billion, representing a year-over-year increase of approximately 41.3%.

• Net profit after deducting non-recurring items1for the full year of 2025 is expected to be approximately RMB13.24 billion, representing a year-over-year increase of approximately 32.6%. The growth rate compared to the adjusted non-IFRS net profit is mainly affected by exchange rate fluctuations.

• Net profit attributable to the owners of the Company1for the full year of 2025 is expected to be approximately RMB19.15 billion. This represents a year-over-year increase of approximately 102.6%, including the investment income from sale of a partial interest in an associate and from divestiture of certain business. Basic earnings per share for the full year of 2025 is expected to be approximately RMB6.70, representing a year-over-year increase of approximately 104.3%.

Other Information

Please be reminded that the above numbers are preliminary estimates only. WuXi AppTec will provide additional details when the Company formally releases its audited 2025 Annual Report on March 24, 2026.

For more information, please refer to the Company's related announcements.

Scan the QR code to view the announcement

[1] Net profit after deducting non-recurring items and net profit attributable to the owners of the Company are both prepared in accordance with China Accounting Standards for Business Enterprises (CAS).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責(zé)聲明：本文僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請?jiān)凇杆幟骺档隆刮⑿殴娞柣貜?fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。